328 related articles for article (PubMed ID: 28681171)
1. A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Rugo HS; Trédan O; Ro J; Morales SM; Campone M; Musolino A; Afonso N; Ferreira M; Park KH; Cortes J; Tan AR; Blum JL; Eaton L; Gause CK; Wang Z; Im E; Mauro DJ; Jones MB; Denker A; Baselga J
Breast Cancer Res Treat; 2017 Oct; 165(3):601-609. PubMed ID: 28681171
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
Baselga J; Morales SM; Awada A; Blum JL; Tan AR; Ewertz M; Cortes J; Moy B; Ruddy KJ; Haddad T; Ciruelos EM; Vuylsteke P; Ebbinghaus S; Im E; Eaton L; Pathiraja K; Gause C; Mauro D; Jones MB; Rugo HS
Breast Cancer Res Treat; 2017 Jun; 163(3):535-544. PubMed ID: 28324268
[TBL] [Abstract][Full Text] [Related]
3. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Schmid P; Sablin MP; Bergh J; Im SA; Lu YS; Martínez N; Neven P; Lee KS; Morales S; Pérez-Fidalgo JA; Adamson D; Gonçalves A; Prat A; Jerusalem G; Schlieker L; Espadero RM; Bogenrieder T; Huang DC; Crown J; Cortés J
Breast Cancer Res; 2021 Jan; 23(1):8. PubMed ID: 33451345
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
[TBL] [Abstract][Full Text] [Related]
5. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Baselga J; Campone M; Piccart M; Burris HA; Rugo HS; Sahmoud T; Noguchi S; Gnant M; Pritchard KI; Lebrun F; Beck JT; Ito Y; Yardley D; Deleu I; Perez A; Bachelot T; Vittori L; Xu Z; Mukhopadhyay P; Lebwohl D; Hortobagyi GN
N Engl J Med; 2012 Feb; 366(6):520-9. PubMed ID: 22149876
[TBL] [Abstract][Full Text] [Related]
6. Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.
Di Cosimo S; Sathyanarayanan S; Bendell JC; Cervantes A; Stein MN; Braña I; Roda D; Haines BB; Zhang T; Winter CG; Jha S; Xu Y; Frazier J; Klinghoffer RA; Leighton-Swayze A; Song Y; Ebbinghaus S; Baselga J
Clin Cancer Res; 2015 Jan; 21(1):49-59. PubMed ID: 25320355
[TBL] [Abstract][Full Text] [Related]
7. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Jerusalem G; de Boer RH; Hurvitz S; Yardley DA; Kovalenko E; Ejlertsen B; Blau S; Özgüroglu M; Landherr L; Ewertz M; Taran T; Fan J; Noel-Baron F; Louveau AL; Burris H
JAMA Oncol; 2018 Oct; 4(10):1367-1374. PubMed ID: 29862411
[TBL] [Abstract][Full Text] [Related]
8. Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer.
Seiler M; Ray-Coquard I; Melichar B; Yardley DA; Wang RX; Dodion PF; Lee MA
Clin Breast Cancer; 2015 Feb; 15(1):60-5. PubMed ID: 25239224
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Yardley DA; Ismail-Khan RR; Melichar B; Lichinitser M; Munster PN; Klein PM; Cruickshank S; Miller KD; Lee MJ; Trepel JB
J Clin Oncol; 2013 Jun; 31(17):2128-35. PubMed ID: 23650416
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Pritchard KI; Burris HA; Ito Y; Rugo HS; Dakhil S; Hortobagyi GN; Campone M; Csöszi T; Baselga J; Puttawibul P; Piccart M; Heng D; Noguchi S; Srimuninnimit V; Bourgeois H; Gonzalez Martin A; Osborne K; Panneerselvam A; Taran T; Sahmoud T; Gnant M
Clin Breast Cancer; 2013 Dec; 13(6):421-432.e8. PubMed ID: 24267730
[TBL] [Abstract][Full Text] [Related]
11. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
[TBL] [Abstract][Full Text] [Related]
12. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.
Brana I; Berger R; Golan T; Haluska P; Edenfield J; Fiorica J; Stephenson J; Martin LP; Westin S; Hanjani P; Jones MB; Almhanna K; Wenham RM; Sullivan DM; Dalton WS; Gunchenko A; Cheng JD; Siu LL; Gray JE
Br J Cancer; 2014 Nov; 111(10):1932-44. PubMed ID: 25290091
[TBL] [Abstract][Full Text] [Related]
13. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.
Beaver JA; Park BH
Future Oncol; 2012 Jun; 8(6):651-7. PubMed ID: 22764762
[TBL] [Abstract][Full Text] [Related]
14. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Yardley DA; Noguchi S; Pritchard KI; Burris HA; Baselga J; Gnant M; Hortobagyi GN; Campone M; Pistilli B; Piccart M; Melichar B; Petrakova K; Arena FP; Erdkamp F; Harb WA; Feng W; Cahana A; Taran T; Lebwohl D; Rugo HS
Adv Ther; 2013 Oct; 30(10):870-84. PubMed ID: 24158787
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.
Frappaz D; Federico SM; Pearson AD; Gore L; Macy ME; DuBois SG; Aerts I; Iannone R; Geschwindt R; Van Schanke A; Wang R; Geoerger B
Eur J Cancer; 2016 Jul; 62():9-17. PubMed ID: 27185573
[TBL] [Abstract][Full Text] [Related]
16. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
17. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
Robertson JF; Ferrero JM; Bourgeois H; Kennecke H; de Boer RH; Jacot W; McGreivy J; Suzuki S; Zhu M; McCaffery I; Loh E; Gansert JL; Kaufman PA
Lancet Oncol; 2013 Mar; 14(3):228-35. PubMed ID: 23414585
[TBL] [Abstract][Full Text] [Related]
18. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Rugo HS; Seneviratne L; Beck JT; Glaspy JA; Peguero JA; Pluard TJ; Dhillon N; Hwang LC; Nangia C; Mayer IA; Meiller TF; Chambers MS; Sweetman RW; Sabo JR; Litton JK
Lancet Oncol; 2017 May; 18(5):654-662. PubMed ID: 28314691
[TBL] [Abstract][Full Text] [Related]
19. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
Kwa M; Li X; Novik Y; Oratz R; Jhaveri K; Wu J; Gu P; Meyers M; Muggia F; Speyer J; Iwano A; Bonakdar M; Kozhaya L; Tavukcuoglu E; Budan B; Raad R; Goldberg JD; Unutmaz D; Adams S
Breast Cancer Res Treat; 2018 Feb; 168(1):57-67. PubMed ID: 29124456
[TBL] [Abstract][Full Text] [Related]
20. Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.
Oza AM; Pignata S; Poveda A; McCormack M; Clamp A; Schwartz B; Cheng J; Li X; Campbell K; Dodion P; Haluska FG
J Clin Oncol; 2015 Nov; 33(31):3576-82. PubMed ID: 26077241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
